IPM Biotech

IPM Biotech (生创精准医疗科技有限公司) is a cell technology and regenerative medicine company founded in 2015 by a team of renowned returnee scientists specializing in stem cells and regenerative medicine. The company has built an integrated industrial ecosystem spanning upstream cell storage, midstream drug R&D and creation, and downstream cell technology research with clinical translation.

Core Capabilities:

• Stem cell-based drug R&D, with proprietary expertise in umbilical cord blood-derived mesenchymal stem cells (uMSCs)
• Immune cell therapeutic technology development
• Genetically modified cell lines and biological reagents R&D
• Cell resource banking and storage services (immune cells, umbilical cord blood stem cells, newborn stem cells, adipose-derived stem cells)
• Clinical research and translation of cell therapies

Therapeutic Focus: The company develops cell therapies targeting cardiovascular disease, diabetes, Parkinson's syndrome, Alzheimer's disease, liver cirrhosis, joint disease, leukemia, and tumor immunotherapy. Immune cell therapy is positioned as an emerging treatment modality for cancer patients.

Infrastructure & Platform: The company operates a proprietary platform described as "1 Institute, 1 Library, 2 Bases, 3 Centers" for umbilical cord blood stem cell drug R&D and technology translation. It holds China's only domestically-owned intellectual property for umbilical cord blood stem cell injection production lines. In 2022, the company launched the "Cell Ark" initiative focusing on cell drug development, clinical research and translation, and cell resource library construction.

Geographic Presence: Headquarters in Hangzhou with operations across Hainan (Free Trade Port), Zhoushan (China Free Trade Zone), Chongqing, Jinan, Zhengzhou, Hong Kong, and Bangkok, Thailand.